ClinicalTrials.gg
RecruitingNCT05440149PORT-N1Updated Nov 29, 2024

The Postoperative Radiotherapy in N1 Breast Cancer Patients

A Phase 3 interventional study of No PMRT for mastectomy / No regional RT for BCS and PMRT for mastectomy / WBI + Regional RT for BCS in Radiotherapy and Breast Cancer, sponsored by Seoul National University Hospital. Recruiting at 1 site in Korea, Republic of. Open to female participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2024-11-29.

Sponsored by Seoul National University Hospital · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2022; still recruiting 4 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,106
Allocation
Randomized
Ages
19 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 50 studies in Breast Neoplasms by Seoul National University Hospital — 13 open to participants now, 21 under way, 3 of them phase 3. Breast Neoplasms · Seoul National University Hospital.

Planned enrollment
2nd of 28
1,106 · median 114
Started
2022
with 7 others
Phase 3
5 of 50
3 open now
Primary completion
2026-12
later than 14 of 20 live
Registered
40th of 50
by date

Among the 50 studies in Breast Neoplasms by Seoul National University Hospital, this one is the 2nd largest by planned enrollment of the 28 interventional ones that give a count, is one of 8 that started in 2022, is one of 5 in phase 3, reaches primary completion later than 14 of the 20 other live ones, and was the 40th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

13 of the 50 studies in Breast Neoplasms by Seoul National University Hospital are open now, in 1 country. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 13 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 19 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies in Breast Neoplasms by Seoul National University Hospital, or all of them as a file.
02

Study summary

This study is a multicenter, randomized, phase 3 clinical trial in patients with breast cancer, randomizing radiotherapy group (postmastectomy radiation therapy (PMRT)/whole breast irradiation plus regional radiotherapy (WBI+regional RT) versus and no PMRT/WBI alone group. This is a non-inferiority study aiming that there is no significant difference in the 7-year disease-free survival rate between the two groups.

Read the detailed description

1:1 randomization to the control group and experimental group, stratified by the type of surgery (breast-conserving surgery (BCS) versus mastectomy) and the type of histologic type (triple negative breast cancer (TNBC) versus non-TNBC)

The control group:

  • If patients received BCS, WBI+Regional RT
  • If patients received mastectomy, PMRT

The experimental group:

  • If patients received breast conserving surgery, WBI alone
  • If patients received mastectomy, No PMRT
03

Conditions studied

  • Radiotherapy
  • Breast Cancer

Browse trials for

Keywords

  • Breast Cancer
  • Radiotherapy
  • Omission
  • Breast Conserving Surgery
  • Mastectomy
  • TNM pathologic stage N1
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged 19 years or older.
  • A female patient who underwent breast-conserving surgery or mastectomy for invasive breast cancer.
  • Patient with stage pN1 after surgery on histopathologic examination.

    • However, if mastectomy was performed, 5 or more nodes should be resected in the case of 1 positive node, and axillary lymph node dissection (ALND) should be performed in case of 2 or 3 positive nodes.
  • Patients undergoing or planning to undergo hormone therapy in the case of hormone receptor positive.
  • Patients who have received or are expected to undergo targeted therapy in the case of human epidermal growth factor receptor(HER)-2 positive.
  • Patients with (ECOG) Scale 0-2.
  • Patients who agreed to participate in the study.

Exclusion criteria

Exclusion Criteria:

  • Patients who have received prior [] chemotherapy.
  • Patients receiving radiation therapy for salvage or palliative purposes.
  • Patients with stage T4.
  • Patients with ipsilateral supraclavicular and internal mammary lymph node or distant metastases.
  • Male breast cancer patient.
  • Patients who have previously received radiation therapy to the ipsilateral breast or supraclavicular region.
  • Patients having a history of cancer other than thyroid cancer, cervical carcinoma in situ, or skin cancer.
  • Patients diagnosed with ductal breast carcinoma in situ, lobular carcinoma in situ, phyllodes, metaplastic cancer, or benign tumors based on histological diagnosis.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,106 participants (estimated)

Study arms

  • Active comparator
    The Control group

    * If patients received mastectomy, post-mastectomy radiation therapy (PMRT) should be performed. * If patients received breast conserving surgery (BCS), whole breast irradiation (WBI) + Regional radiotherapy (RT) should be performed.

    Radiation: PMRT for mastectomy / WBI + Regional RT for BCS

  • Experimental
    The Experimental group

    * If patients received mastectomy, No PMRT should be performed. * If patients received BCS, WBI alone should be performed.

    Radiation: No PMRT for mastectomy / No regional RT for BCS

Interventions

  • RadiationNo PMRT for mastectomy / No regional RT for BCS

    * Regional RT includes high-tangent field, and can include undissected axilla. * The definition of high-tangent is that the upper margin of the radiotherapy field located within 2 cm of the humeral head to include axillary levels I and II. * Both hypofractionated and conventionally fractionated radiation therapy are allowed, and 3-dimensional or intensity modulated radiotherapy are allowed. The electron beam can also be used.

  • RadiationPMRT for mastectomy / WBI + Regional RT for BCS

    * Regional RT includes high-tangent field, and can include undissected axilla. * The definition of high-tangent is that the upper margin of the radiotherapy field located within 2 cm of the humeral head to include axillary levels I and II. * Both hypofractionated and conventionally fractionated radiation therapy are allowed, and 3-dimensional or intensity modulated radiotherapy are allowed. The electron beam can also be used.

06

What researchers measure

Primary outcomes

  1. Disease-Free Survival

    Time from randomization to local recurrence, regional recurrence, distant metastases, or breast cancer-related death.

    Time frame: 7-Year

Secondary outcomes

  1. Locoregional-Recurrence Free Survival

    Time from randomization to recurrence of tumors in the ipsilateral chest wall, breast or regional lymph nodes (ipsilateral axillary/internal mammary/supraclavicular lymph nodes) or breast cancer-related death. \*\* Recurrence should be confirmed by histological diagnosis, but local recurrence can be diagnosed by clinical examination only when regional/remote or distant metastases already exist.

    Time frame: 7-Year

  2. Distant Metastases Free Survival

    Time from randomization to the development of distant metastases or breast cancer-related death.

    Time frame: 7-Year

  3. Overall Survival

    Time from randomization to the death due to any cause.

    Time frame: 7-Year

Other outcomes

  1. Dermatitis

    Common Terminology Criteria for Adverse Events (CTCAE) 5.0 Scale

    Time frame: Every 6 month during 1 years, then every 1 year till 7 years after randomization

  2. Radiation-related pneumonitis

    Common Terminology Criteria for Adverse Events (CTCAE) 5.0 Scale

    Time frame: Every 6 month during 1 years, then every 1 year till 7 years after randomization

  3. Major complication rate for reconstructed breast

    For patients who received breast reconstruction after mastectomy

    Time frame: Every 6 month during 1 years, then every 1 year till 7 years after randomization

  4. Occurence of contralateral in-situ or invasive breast cancer

    Pathologic confirmation

    Time frame: Every 6 month during 1 years, then every 1 year till 7 years after randomization

  5. Major cardiac event

    Myocardial infarction / Ischemic heart failure / Unstable angina / Sudden death

    Time frame: Every 6 month during 1 years, then every 1 year till 7 years after randomization

  6. Ipsilateral rib fracture

    Symptom or radiologic diagnosis

    Time frame: Every 6 month during 1 years, then every 1 year till 7 years after randomization

  7. Arm Lymphedema

    Symptom / Diagnosis from the related-department (e.g. rehab) / Expert opinion

    Time frame: Every 6 month during 1 years, then every 1 year till 7 years after randomization

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Lee TH, Chang JH, Jang BS, Kim JS, Kim TH, Park W, Kim YB, Kim SS, Han W, Lee HB, Shin KH. Protocol for the postoperative radiotherapy in N1 breast cancer patients (PORT-N1) trial, a prospective multicenter, randomized, controlled, non-inferiority trial of patients receiving breast-conserving surgery or mastectomy. BMC Cancer. 2022 Nov 16;22(1):1179. doi: 10.1186/s12885-022-10285-0. PubMed 36384573 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2022 (actual). Primary completion is estimated for Dec 2026, 52 months after the start.

Of 328 non-industry phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 79 months of starting (the median), counting those still running; a quarter within 50 and three quarters within 127. This study's planned 52 months is below that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 27, 2022
First posted
Jun 30, 2022
StartActual
Aug 1, 2022
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2033
Last update
Nov 29, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 29, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05440149
Responsible party
Kyung Hwan Shin (Professor, Chairman, Seoul National University Hospital) — Principal investigator
First posted
Jun 30, 2022
Start date
Aug 1, 2022
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2033 (estimated)
Last update
Nov 29, 2024

Study contacts

Kyung Hwan Shin, MD. PhD.
Contact
radiat@snu.ac.kr
+82-2-2072-2524
Bum-Sup Jang, MD. PhD.
Contact
bigwiz83@snu.ac.kr
+82-2-2072-1161
Kyung Hwan Shin, MD. PhD.
principal investigator · Seoul National University Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion